54 results
424B1
BIOL
Biolase Inc
14 Feb 24
Prospectus with pricing info
9:21pm
net operating loss carryforwards of approximately $123 million and $72.6 million, respectively. This also resulted in a reduction of federal tax R&D credit
8-K
EX-99.1
ktheucghz0g94hnsio
8 Jun 22
Material Modifications to Rights of Security Holders
6:06am
8-K
EX-99.1
2va6qylwbf6k 93skaop
27 Oct 20
Regulation FD Disclosure
1:43pm
8-K
EX-99.1
pv7yusz75gy7q4aqtko
26 Mar 20
Biolase Reports 2019 Fourth Quarter; Net Revenue Increased 18% Sequentially
4:23pm
8-K
EX-99.1
q3khnx976 8b8nhr8
6 Nov 19
Biolase Reports Third Quarter 2019 Results
4:10pm
FWP
rchhmx ip9awwmzb8zgd
4 Oct 19
Free writing prospectus
7:41pm
8-K
EX-99.2
cnn2b4903bq7ytebroer
2 Sep 14
Biolase Names Jeffrey M. Nugent Permanent President and Chief Executive Officer
12:00am
8-K
EX-99.1
7hzp2oag1 o9c45qsam3
14 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
3uohdt65kd c3pldww
10 Sep 13
Regulation FD Disclosure
12:00am